Search
CA-170
go.drugbank.com/drugs/DB15772InvestigationalCA-170 is a selective, small molecule inhibitor of PD-L1.
Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProlgolimab
go.drugbank.com/drugs/DB16740InvestigationalCategories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsArdeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnArdeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.
Zuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalKnown drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. … This drug is a liquid. This compound belongs to the thioxanthenes.
Elbasvir
go.drugbank.com/drugs/DB11574Approved[L10253] Elbasvir and [grazoprevir] are used with or without [ribavirin] with the intent to cure, or achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% … Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.
Rilapladib
go.drugbank.com/drugs/DB05119InvestigationalIt is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47526] It is considered one of the most likely agents to be used in a biological attack. … Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade. … [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway.